TGF-β1 (C-509T) Gene Promoter Polymorphism and its Influence on Chronic Pancreatitis

Kavutharapu Sri Manjari, Akka Jyothy, Porika Shravan Kumar, Boddu Prabhakar, Prathibha Nallari, Ananthapur Venkateshwari

ABSTRACT

AIM: Chronic pancreatitis is a long-standing inflammation of the pancreas that alters its normal structure and function. The aim of the study is to investigate the role of promoter polymorphism in the TGF-β1-509 (C/T) gene in chronic pancreatitis.

METHODS: A total of 100 chronic pancreatitis patients and 100 control subjects were included in the present study. The genotyping of promoter polymorphism in the TGF-β1-509 (C/T) gene was carried out by tetra-primer ARMS PCR followed by agarose gel electrophoresis. The serum TGF-β1 levels were measured by enzyme-linked immunosorbent assay. Statistical analysis was applied for the significance of the results.

RESULTS: The genotype distribution was 57% of C/C, 38% of C/T and 5% of T/T in control subjects, whereas in chronic pancreatitis patients they were 37% of C/C, 39% of C/T, and 24% of T/T genotype respectively. A significant variation in the distribution of T allele was observed in the patient group compared to control subjects [OD = 0.410 (0.261-0.643), p<0.000**]. There was a significantly higher levels of TGF-β1 levels in CP patients compared to healthy subjects.

CONCLUSION: The present study found a significant association between the TGF-β1-509 (C/T) gene promoter polymorphism and chronic pancreatitis. Further, the levels were also found to be elevated in patients compared to control subjects. Thus, TGF-β1-509 (C/T) genotype can be considered as one of the risk factor in the etiology of the disease.

INTRODUCTION

Chronic pancreatitis (CP) is characterized by the slow, progressive development of structural abnormalities within the pancreas. These morphological changes lead to progressive pancreatic functional impairment[1]. One of the key features of chronic pancreatitis is pancreatic fibrosis, which has received wide attention over the past few years, largely due to the identification and characterization of stellate cells in the pancreas. The progressive replacement of pancreas-specific tissue by ECM-rich connective tissue may lead to the development of an exocrine and endocrine insufficiency of the gland.

In human tissues, normal homeostasis requires intricately balanced interaction between cells and the network of secreted proteins known as the extracellular matrix (ECM). These cooperative interactions involve numerous cytokines acting through specific cell-surface receptors. The balance between the cells and the extracellular matrix when perturbed can result in a disease[2]. This is clearly evident by...
the interaction mediated by the cytokine transforming growth factor β1 (TGF-β1), a growth factor demonstrating documented and well-known profibrogenic activity[3].

Transforming growth factor-β1 is a cytokine produced by both immune and non immune cells. TGF-β1 controls the differentiation, proliferation, and state of activation of all immune cells, wound healing and angiogenesis and is implicated in immune abnormalities linked to cancer, autoimmunity, opportunistic infections, and fibrotic complications. The present study is aimed at evaluating the qualitative and quantitative role of TGF β1 in the etiology of chronic pancreatitis.

METHODS

Study population
A total of 200 unrelated individuals were included in the present study. One hundred clinically evaluated chronic pancreatitis (CP) patients referred to the Gastroenterology unit of Gandhi Hospital and Osmania General Hospital, Hyderabad during the two years from 2008 to 2010 were included in the present study. An equal number of healthy control subjects were randomly selected among the individuals visiting our Institute for regular health checkup was also included for comparative studies. A structured proforma was used to seek information on dietary habits, smoking, alcohol consumption, family history etc. Written informed consent was obtained from all the subjects, before initiation of the study. The study was also approved by our Institutional Ethical committee.

DNA separation
5ml of venous blood was drawn from each individual in vacutainers with and without EDTA for the separation of plasma and serum respectively and stored at -70°C until use. Genomic DNA was isolated from whole blood by following the salting out procedure of Lahiri et al (1991)[6].

Genotyping of the TGF-β1 gene
The polymorphism for TGF-β1 C-509T (rs1800469) was genotyped based on Amplification Refractory Mutation System-Polymerase Chain Reaction (ARMS-PCR) method. The allele-specific primers are as follows: forward primer, 5’CTACGGCGTTGAGTCTGAG 3’, and reverse primer, 5’AAGGGGCAACAGGACACCTTGGG 3’ for the C allele and 5’ AAGGGGCAACAGGACACCTTGGGA 3’ for the T allele. A 349 base pair region (-488 to -836 from the transcription start site) in the TGF-β1 gene promoter was targeted for amplification. The optimized reaction conditions consisted of 40 ng of genomic DNA in a reaction volume of 15 μL containing 1X reaction buffer, 1.5 μM MgCl2, 30 μM of each dNTP, 0.16 μM of each primer, and 0.3U of Taq DNA polymerase. The cycling conditions were as follows: an initial denaturation at 94°C for 4 minutes, followed by 35 cycles at 94°C for 30 s, 61°C for 20 s and 72°C for 30 s. The final extension step was at 72°C for 6 min.

The amplified products were electrophoresed on an agarose gel (1.5 %) stained with ethidium bromide. The presence of 349bp bands in both the C and T lanes based on 100–base pair ladder indicated heterozygous CT genotype whereas the presence of 349 bp band either in C lane or T lane represents homozygous CC genotype and homozygous TT genotype respectively (Figure 1).

Estimation of TGF-β1 levels by ELISA
Concentrations of TGF-β1 (Invitrogen®) in plasma were estimated using a commercial ELISA kit according to the manufacturer’s protocols. In brief, 50 μl detector antibody was added to different wells designated as samples and standards. 50 μL of standard or control samples were added to each well. After 2 hours of incubation at room temperature on a constant shaker (500 ± 50 rpm), the reaction solution was aspirated and the wells were washed 4 times with wash buffer; 100 μL of TGF-β1 conjugate was then added to each well and incubated for another 30 min on the shaker at room temperature. Then the aspiration/wash steps were repeated as mentioned above, followed by adding of 100 μL of substrate solution to each well. The microplate was allowed to stand for 30 min at room temperature in the dark. After adding 100 μL of stop solution, the optical density at 450 nm of each sample was determined and represented in ng/mL.

The TGF-β1 concentrations for each sample were calculated from the standard curve obtained.

Statistical analysis
Differences among subject groups in clinical characteristics were analysed with t-tests or Fisher’s two-tailed exact tests. Genotype frequencies were tabulated by direct counting and allele frequencies estimated from the observed number of genotypes. Chi-square (χ²) analysis was used to test for deviation of allele frequencies from Hardy–Weinberg equilibrium. The distributions of the TGF-β1 genotype and allele frequencies in healthy and CP group were also analyzed by Chi-square or Fisher’s two-tailed exact tests. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were also assessed. The relationship between genotype and disease status was analyzed by multiple logistic regression analysis for potential confounding factors including age, gender, smoking, consanguinity and alcohol status. TGF-β1 serum levels within CP and healthy groups were compared between subjects carrying different genotypes using the “t” test. P-values <0.05 were considered to be statistically significant. Clinical parameters were compared with repeated measure ANOVA test. The data analysis was performed using a statistical package (SPSS Inc., version 19.0, Chicago, IL, USA).

RESULTS
The study population consisted of 100 CP patients of which 94 (94.0%) males and 6 (6.0%) females with an age range of 13-70 years, as well as 100 control subjects of an age range 20-70 [(95.0%) males and 5 (5.0%) females] were considered (Table 1). Patients and
control subjects were derived from the same geographic location and are representative of South Indian population from Andhra Pradesh. A significant difference was observed with respect to smokers (<0.000**) and alcoholics (<0.000**) in patients compared to control subjects.

Table 2 gives the genotype distribution of TGF-β1 (-509 C/T) gene in control subjects and patients with chronic pancreatitis. Among the controls the genotype distribution was 57% of C/C, 38% of C/T and 5% of T/T, whereas in chronic pancreatitis patients 37% were of C/C, 39% of C/T, and 24% were of T/T genotype. A significant variation was observed in the patient group compared to control subjects [OR=0.410 (0.261-0.643), p<0.000**] with respect to allelic distribution.

Table 3 gives the mean serum TGF-β1 levels with respect to TGF-β1genotype between controls and chronic pancreatitis patients. A significant increase in the serum TGF-β1 levels in CP patients (219.30±163.907) was observed when compared to controls (168.55±100.22) (p=0.0001**).

**DISCUSSION**

Chronic pancreatitis an inflammatory, usually painful, condition characterized by progressive glandular destruction, fibrosis and loss of endocrine and exocrine function culminating in pancreatic failure, along with associated complications to the surrounding viscera and vasculature[5].

Fibrosis is a wound-healing response by which the body attempts to repair itself following injury. Acute and more commonly, chronic injury from a wide variety of insults leads to organ fibrosis. Organ systems have different cellular and molecular mechanisms that result in fibrosis[6]. Fibrous tissue contains extracellular matrix but in different ratios to normal tissue. In particular, there is a significantly increased amount of type I collagen, with progressive fibrosis eventually leading to distortion of the normal organ architecture. The distorted architecture, along with loss of normal cellularity may, lead to a loss of function of the underlying organ[7].

Pancreatic fibrosis is associated with major alterations in both the quantity and composition of the extracellular matrix (ECM). Accumulation of ECM, including fibrillar collagens, fibronectin, laminin, hyaluronic, and proteoglycans, results from both increased synthesis and decreased degradation[8]. An imbalance of the two dynamic processes, fibrogenesis and fibrolysis leads to fibrosis. Genes that govern the production and degradation of fibrous tissue are important with regard to the etiology of chronic pancreatitis. These genes could represent genetic markers of progression rather than susceptibility towards a certain disease.

Cytokines play an important role in regulating the immune response during acute pancreatitis[9,10], and cytokines may also be secreted by inflammatory cells that infiltrate the pancreas in chronic pancreatitis[10]. As TGF-β1 is one of the most important profibrogenic cytokine and a potent activator of pancreatic stellate cells, its role in fibrogenesis and fibrolysis cannot be ruled out. The expression of TGF-β1 is influenced by polymorphisms in the TGF-β1 gene. In particular, there is a C>T promoter polymorphism at nucleotide position –509 (position relative to transcriptional start site defined in GenBank NM_000660 and NT_011189) that alters a Yin Yang 1 (YY1) transcription factor consensus binding site (–CCATCTC/TG–) and is associated with higher circulating concentrations of TGF-β1 in plasma[11]. TGF-β1 has been shown to be of particular importance in biosynthesis and turnover of extracellular matrix. The present study revealed a significant association of TT genotype and T allele with the disease compared to control subjects.

Pancreatic stellate cells may play a central role in pancreatic fibrosis in regulating the fibrotic destruction of the organ[12,13]. Results from in vitro studies revealed that these cells are stimulated by alcohol and other inflammatory cytokines[14,15]. Earlier studies with animal models have shown that cytokines participate in the immunologic processes during chronic pancreatitis[16,17]. Awdad et al.[18] (1998) found an association between leucine at codon 10 and elevated TGF-β1 concentrations in patients with cystic fibrosis. A preliminary study by Howell et al.[19] showed no association between TGF-β1 +915 polymorphism and CP. Studies by Yamada et al.[20] (1998) and Yokota et al.[21] (2000) revealed conflicting results and linked the proline at codon 10 with the highest serum concentrations in Japanese[22,23]. Elevated levels of TGF-β1 observed in the present study may stimulate transcription and biosynthesis of extracellular matrix proteins and functions as an activator of pancreatic stellate cell proliferation. These alterations may lead to pancreatic fibrosis and ductular cell proliferation, resulting in chronic pancreatitis.
It is a well-defined fact that TGF-β1 strongly stimulates the synthesis of extracellular matrix components, including collagen, fibronectin, and proteoglycan, and a major candidate in the fibrogenesis that occurs in different chronic inflammatory diseases, including chronic pancreatitis. Earlier studies by Mola et al 1999, on the pancreatic tissue samples of chronic pancreatitis patients in situ hybridization and immunohistochemistry have clearly showed overexpression of TGF-β1 suggesting its role in CP[23]. Similar studies by Satoh et al 1998 have shown a significant increase in TGF-β1 expression[20]. A study by Muller et al 1999 on transgenic mice showed an enhanced TGF-β1 expression in the development of fibrosis and inflammation in pancreas during CP[21].

In conclusion, TGF-β1-509 (C/T) gene can be considered as one of the biomarker in the etiology of the disease and may contribute to the pathogenesis of chronic pancreatitis by increasing proliferation of pancreatic stellate cells. Thus, further analysis on a larger sample size is required to confirm the possible association of TGF-β1 in chronic pancreatitis.

ACKNOWLEDGMENTS

The authors acknowledge financial support from University Grants Commission (UGC), New Delhi [File No: 36-185/2008 (SR)].

CONFLICT OF INTERESTS

There are no conflicts of interest with regard to the present study.

REFERENCES

1 Dominguez-Munoz JE, Manes G, Pieramico O, Buchler MW, Malfertheiner P. Effect of pancreatic ductal and parenchymal changes on exocrine function in chronic pancreatitis. Pancreas 1995; 10: 31-35

2 Kihara Y, Tashiro M, Nakamura H, Yamaguchi T, Yoshikawa H, Otsuki M. Role of TGF-beta1, extracellular matrix, and matrix metalloproteinase in the healing process of the pancreas after induction of acute necrotizing pancreatitis using arginine in rats. Pancreas 2001; 23: 288-295

3 Blobe GC, Schiemed WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-1358

4 Lahiri DK, Nurnberger JI. A rapid non-enzymatic method for the preparation of HMW DNA from blood. Nucleic Acids Res 1991; 19: 5444

5 Hirschfeld GM, Gimson AE. Chronic pancreatitis. Medicine 2007; 35: 320-324

6 Hayakawa T, Kondo T, Shibata T, Noda A, Suzuki T, Nakano S. Relationship between pancreatic exocrine function and histological changes in chronic pancreatitis. Am J Gastroenterol 1992; 87: 1170-1174

7 Bozkurt T, Braun U, Leferink S, Gilly G, Lux G. Comparison of pancreatic morphology and exocrine functional impairment in patients with chronic pancreatitis. Gut 1994; 35: 1132-1136

8 Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, Gaster R, Callahan JF, OLso BA. Inhibition of Transforming Growth Factor (TGF)-β1-Induced Extracellular Matrix with a Novel Inhibitor of the TGF-βType I Receptor Kinase Activity: SB-431542. Mol Pharmacol 2002; 62: 58-64

9 de Beaux AC, Goldie AS, Ross JA, Carter DC, Fearon KC. Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis. Br J Surg 1996; 83: 349-353

10 Sauer L, Reber P, Schaffner T, Büchler MW, Buri C, Kappeller A, Walz A, Friess H, Müller C. Differential expression of chemokines in normal pancreas and in chronic pancreatitis. Gastroenterology 2000; 118: 356-67

11 O’Kane S, Ferguson MW. Transforming growth factor and wound healing. Int J Biochem Cell Biol 1997; 29: 63-78

12 Apte MV, Haber PS, Applegate TL, Norton JD, Mc Caughan GW, Korsten MA, Pirola RC, Wilson JS. Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut 1998; 43: 128-133

13 Bachem MG, Schneider E, Gross H, Weidenbach H, Schmid RM, Menke A, Siech M, Beger H, Grüner A, Adler G. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology 1998; 115: 421-432. [PMID: 9679048]

14 Apte MV, Phillips PA, Fahmny RG, Darby SJ, Rodgers SC, Mc Caughan GW, Korsten MA, Pirola RC, Naidoo D, Wilson JS. Does alcohol directly stimulate pancreatic fibrogenesis? Studies with rat pancreatic stellate cells. Gastroenterology 2000; 118: 780-794

15 Mews P, Phillips P, Fahmny R, Korsten M, Pirola R, Wilson J, Apte M. Pancreatic stellate cells respond to inflammatory cytokines: potential role in chronic pancreatitis. Gut 2000; 50: 535-541

16 Sparmann G, Behrend S, Merkord J, Kleine HD, Graser E, Ritter T. Cytokine mRNA levels and lymphocyte infiltration in pancreatic tissue during experimental chronic pancreatitis induced by dibutylin chloride. Dig Dis Sci 2001; 46: 1647-1656

17 Xie MJ, Motoo Y, Su SB, Sawabu N. Expression of tumour necrosis factor-alpha, interleukin-6 and interferon-gamma in spontaneous chronic pancreatitis in the WBN/Kob rat. Pancreas 2001; 22: 400-408

18 Awad MR, El-Gamal A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotype variation in the transforming growth factor-beta gene: association with transforming growth factor-beta 1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998; 66: 1014-1020

19 Howell WM, Peal PJ, Shee FW, Rose-Zerilli MJ, Armstrong T, Johnson CD, Fine DR, Iredale JP, Bateman AC. Influence of cytokine and ICAM-1 gene polymorphisms on susceptibility to chronic pancreatitis. J Clin Pathol 2005; 58: 595-599

20 Yamada Y, Miyauuchi A, Goto J, Takagi Y, Okuzumi H, Kanematsu M, Takai H, Harada A, Ikeda K. Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J Bone Miner Res 1998; 13: 1569-1576

21 Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y. Association of a T29→C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000; 101: 2783-2787

22 di Mola FF, Friers H, Martignoni ME, Di Sebastianio P, Zimmermann A, Innocenti P, Gruber H, Gold LI, Koc M, Büchler MW. Connective tissue growth factor is a regulator for fibrosis in chronic pancreatitis. Ann Surg 1999; 230: 63-71

23 Satoh K, Shimosegawa T, Hirota M, Koizumi M, Toyota Y. Expression of transforming growth factor beta 1 (TGF-β1) and its receptors in pancreatic duct cell carcinoma and in chronic pancreatitis. Pancreas 1998; 16: 468-474

24 Muller-Pill LAS, Menke A, Yamaguchi H, Elsasser HP, Bachem M, Adler G, Gress TM. TGFβ and the extracellular matrix in pancreatitis. Hepatogastroenterology 1999; 46: 2751-2756

Peer reviewer: Raffaele Pezzilli, Department of Internal medicine and Gastroenterology, Sant’Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy.